Progression of chronic kidney disease among black patients attending a tertiary hospital in Johannesburg, South Africa

Alfred Meremo; Graham Paget; Raquel Duarte; Deogratius Bintabara; Saraladevi Naicker

doi:10.1101/2022.10.06.22280771

Abstract

Background Chronic kidney disease (CKD) is a major public health issue worldwide and is an important contributor to the overall non-communicable disease burden. Chronic kidney disease is usually asymptomatic, and insidiously and silently progresses to advanced stages in resource limited settings.

Methodology A prospective longitudinal study was carried out on black patients with CKD attending the kidney outpatient clinic at Charlotte Maxeke Johannesburg Academic Hospital (CMJAH) in South Africa, between September 2019 to March 2022. Demographic and clinical data were extracted from the ongoing continuous clinic records, as well as measurements of vital signs and interviews at baseline and at follow up. Patients provided urine and blood samples for laboratory investigations as standard of care at study entry (0) and at 24 months, and were followed up prospectively for two (2) years. Data were descriptively and inferentially entered into REDcap and analysed using STATA version 17, and multivariable logistic regression analysis was used to identify predictors of CKD progression.

Results A total of 312 patients were enrolled into the study, 297 (95.2%) patients completed the study, 10 (3.2%) patients were lost to follow and 5 (1.6%) patients died during the study period. The prevalence of CKD progression was 49.5%, while that of CKD remission was 33% and CKD regression was 17.5%. For patients with CKD progression the median age at baseline was 58 (46 - 67) years, the median eGFR was 37 (32 -51) mL/min/1.73 m², median urine protein creatinine ratio (uPCR) was 0.038 (0.016 -0.82) g/mmol and the median haemoglobin (Hb) was 13.1 (11.7 – 14.4) g/dl; 95.2% had hypertension, 40.1% patients had diabetes mellitus and 39.5% had both hypertension and diabetes mellitus. Almost half (48.3%) of patients with CKD progression had severely increased proteinuria and 45.6% had anaemia. Variables associated with higher odds for CKD progression after multivariable logistic regression analysis were severely increased proteinuria (OR 32.3, 95 % CI 2.8 - 368.6, P = 0.005), moderately increased proteinuria (OR 23.3, 95% CI 2.6 - 230.1, P= 0.007), hypocalcaemia (OR 3.8, 95 % CI 1.0 - 14.8, P = 0.047), hyponatraemia (OR 4.5, 95% CI 0.8 - 23.6, P= 0.042), anaemia (OR 2.1, 95% CI 1.0 - 4.3, P= 0.048), diabetes mellitus (OR 1.8, 95 % CI 0.9 - 3.6, P = 0.047), elevated HbA1c (OR 1.8, 95 % CI 1.2 - 2.8, P = 0.007) and current smoking (OR 2.8, 95 % CI 0.9 - 8.6, P = 0.049).

Conclusion Our study identified a higher prevalence of progression of CKD in a prospective longitudinal study of black patients with CKD. Progression of CKD was associated with proteinuria, diabetes mellitus, elevated HbA1c, anaemia, hypocalcaemia, hyponatraemia and current smoking. This is a call for nephrologists and clinicians to be vigilant in identifying CKD patients at risk of CKD progression at early stages as this would allow risk stratification to improve kidney disease outcomes.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

The author(s) received no specific funding for this work.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Not Applicable

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethical approval was obtained from the Human Research Ethics Committee of the University of Witwatersrand, Johannesburg (ethics clearance certificate No. M190553). Written informed consent was obtained from each of the participants before enrolment and embarking on data collection.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Not Applicable

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Not Applicable

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Not Applicable

Footnotes

Contact addresses for authors: GP: Graham.Paget{at}wits.ac.za
RD: Raquel.Duarte{at}wits.ac.za
DB: bintabaradeo{at}gmail.com
SN: Saraladevi.Naicker{at}wits.ac.za

Data Availability

Data cannot be shared publicly because of ethics policy at University of Witwatersrand, the participants signed a consent form, which states that data is exclusively available for professional research staff. Data are available to qualifying organizations and/or individuals from the chairperson of the Human Research Ethics Committee (Medical) of the University of the Witwatersrand, Johannesburg (‘Committee’) who is Dr. Clement Penny, who may be contacted by e-mail on Clement.Penny{at}wits.ac.za) for researchers who meet the relevant ethics criteria for access to these data.

Abbreviations

CKD: chronic kidney diseases;
CMJAH: Charlotte Maxeke Johannesburg Academic Hospital;
CKD-EPI: chronic kidney disease epidemiology collaboration;
ESKD: end stage kidney disease;
T2DM: Type 2 Diabetes Mellitus;
eGFR: estimated glomerular filtration rate;
IDMS: isotope dilution mass spectroscopy;
uPCR: urine protein creatinine ratio;
CCBs: calcium channel blockers;
ACEIs: angiotensin converting enzyme inhibitors;
ARBs: Aldosterone receptors blockers;
KDIGO: kidney disease improving global outcomes;
NCDs: non-communicable diseases;
SSA: sub Saharan Africa;
UK: United Kingdom;
USA: United States of America

The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.